| Ident. | Authors (with country if any) | Title |
|---|
| 000164 (2012) |
A. Marquet [Suisse] ; K. Kupas [Allemagne] ; A. Johne [Allemagne] ; B. Astruc [France] ; A. Patat [France] ; S. Krösser [Allemagne] ; A. Kovar [Allemagne] | The Effect of Safinamide, a Novel Drug for Parkinson's Disease, on Pressor Response to Oral Tyramine: A Randomized, Double‐Blind, Clinical Trial |
| 000242 (2012) |
Bruno Dubois [France] ; Eduardo Tolosa [Espagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew J. Lees [Royaume-Uni] ; Günther Schumann [Allemagne] ; Emmanuelle Pourcher [Canada] ; Julian Gray [Suisse] ; Gail Thomas [Royaume-Uni] ; Jina Swartz [Royaume-Uni] ; Timothy Hsu [États-Unis] ; Margaret L. Moline [États-Unis] | Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study |
| 000329 (2011) |
Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; And Ad Theeuwes [Pays-Bas] | Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials |
| 000493 (2010) |
Robert A. Hauser [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] ; Paolo Barone [Italie] ; Yoshikuni Mizuno [Japon] ; Laurence Salin [France] ; Monika Haaksma [Autriche] ; Nolwenn Juhel [France] ; Werner Poewe [Autriche] | Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease |
| 000503 (2010) |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study |
| 000552 (2010) |
Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas] | Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease |
| 000629 (2009) |
Ray L. Frost [Australie] ; Aurore Soisnard [Australie, France] ; Nicolas Voyer [Australie, France] ; Sara J. Palmer [Australie] ; Wayde N. Martens [Australie] | Thermo‐Raman spectroscopy of selected layered double hydroxides of formula Cu6Al2(OH)16CO3 and Zn6Al2(OH)16CO3 |
| 000814 (2008) |
David Devos [France] ; Kathy Dujardin [France] ; Isabelle Poirot [France] ; Caroline Moreau [France] ; Olivier Cottencin [France] ; Pierre Thomas [France] ; Alain Destée [France] ; Regis Bordet [France] ; Luc Defebvre [France] | Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study |
| 000833 (2008) |
C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics |
| 000866 (2007) |
Christopher G. Goetz [États-Unis] ; Philippe Damier [France] ; Christine Hicking [Allemagne] ; Eugene Laska [États-Unis] ; Thomas Müller [Allemagne] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne] | Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial |
| 000867 (2007) |
Björn Holmberg [Suède] ; Jan-Ove Johansson [Suède] ; Werner Poewe [Autriche] ; Gregor Wenning [Autriche] ; Niall P. Quinn [Royaume-Uni] ; Chris Mathias [Royaume-Uni] ; Eduardo Tolosa [Espagne] ; Adriana Cardozo [Espagne] ; Nil Dizdar [Suède] ; Olivier Rascol [France] ; Tarik Slaoui [France] | Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study |
| 000940 (2007) |
Joyce Colussi-Mas [France] ; Stefanie Geisler [États-Unis] ; Luc Zimmer [France] ; Daniel S. Zahm [États-Unis] ; Anne Bérod [France] | Activation of afferents to the ventral tegmental area in response to acute amphetamine: a double‐labelling study |
| 000963 (2006) |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease |
| 000B30 (2005) |
Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] | End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study |
| 000B84 (2004) |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew J. Lees [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study |
| 000D64 (2002) |
Anh Tua N Phan ; Jean-Louis Mergny [France] | Human telomeric DNA: G‐quadruplex, i‐motif and Watson–Crick double helix |
| 001159 (2000) |
C. Scherfler [Autriche] ; Z. Puschban [Autriche] ; I. Ghorayeb [France] ; G. P Goebel [Autriche] ; F. Tison [France] ; K. Jellinger [Autriche] ; Werner Poewe [Autriche] ; G. K Wenning [Autriche] | Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy) |
| 001288 (1999) |
Valérie Ben [France] ; Olivier Blin [France] ; Bernard Bruguerolle [France] | Time‐dependent Striatal Dopamine Depletion after Injection of 6‐Hydroxydopamine in the Rat. Comparison of Single Bilateral and Double Bilateral Lesions |
| 001378 (1999) |
Jean-Louis Montastruc [France] ; Marc Ziegler [France] ; Olivier Rascol [France] ; Muriel Malbezin [France] | A randomized, double‐blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease |
| 001F57 (1989) |
J. Arnaud [France] ; J. Buyse [Belgique] ; B. Nordlinger [France] ; F. Martin [France] ; J. Pector [Belgique] ; P. Zeitoun [France] ; A. Adloff [France] ; N. Duez [Belgique] | Adjuvant therapy of poor prognosis colon cancer with levamisole: Results of an EORTC double‐blind randomized clinical trial |
| 002009 (1988) |
H. Allain ; J. Denmat ; D. Bentue-Ferrer [France] ; D. Milon [France] ; P. Pignol ; J. M. Reymann [France] ; D. Pape [France] ; O. Sabouraud ; J. Van Den Driessche [France] | RANDOMIZED, DOUBLE‐BLIND TRIAL OF EXIFONE VERSUS COGNITIVE PROBLEMS IN PARKINSON'S DISEASE |
